Australian firm Atomo Diagnostics has collaborated with US-based biotechnology company RPS Diagnostics for the development and commercialisation of next-generation FebriDx tests to diagnose febrile acute respiratory infections (ARI).
Intended for point-of-care use, the rapid, single-use, disposable FebriDx test involves the use of a fingerstick blood sample to assess the immune response of the body to ARIs.
According to Atomo, the test takes less than ten minutes to detect people with a clinically significant underlying infection.
FebriDx is also designed to distinguish between viral and bacterial ARIs by simultaneous and direct identification of Myxovirus resistance protein A (MxA), as well as c-reactive protein (CRP) from the peripheral whole blood.
The intracellular MxA protein is increased during acute viral infection, while the acute-phase inflammatory CRP protein rises in the presence of a clinically significant infection.
Atomo Diagnostics CEO John Kelly said: “We believe that rapid viral versus bacterial differentiation is a critical need.
“We considered a variety of potential partnership opportunities in this area, and believe that FebriDx is the best-positioned technology to achieve the greatest impact.”
Under the partnership, the existing, commercially available, qualitative FebriDx test will leverage Atomo’s all-in-one rapid diagnostic test platform designed to offer a consolidated test.
The platform features an inbuilt safety lancet, calibrated blood collection and delivery system, as well as an integrated push-button buffer delivery mechanism.
RPS Diagnostics president and chief technology / medical officer Dr Robert Sambursky said: “We believe the incorporation of the novel Atomo technology into the existing FebriDx testing system will improve its ease of use and accuracy, allowing for broader acceptance in outpatient settings.”
The new alliance will also see the development of an advanced digital, single-use, disposable version of the FebriDx test.